NeuroMab™ Anti-Alpha Synuclein BBB Shuttle Antibody(NRZP-1022-ZP2538)

Fig.1 Recombinant human α-synuclein antibodies are directed against distinct epitopes.

Recombinant full-length and truncated α-synuclein was coated onto ELISA plates at equal coating concentration (20 μg/ml).

Fig.2 Recombinant human α-synuclein antibodies bind α-synuclein but not β- and γ-synuclein in a direct ELISA.

Recombinant α-, β- and γ-synuclein coated onto ELISA plates at equal coating concentration (2 μg/ml) were incubated with recombinant human α-synuclein antibodies or with a pan synuclein antibody.

Fig.3 Recombinant human α-synuclein antibody NI-202.12F4 binds α-synuclein but not β- and γ-synuclein on Western blot analysis.

Recombinant α-, β- and γ-synuclein (each 750 ng) were subjected to SDS-PAGE and subsequent to Western Blot analysis.

Fig.4 Recombinant NI-202.12F4 shows high affinity binding to wild type and disease causing mutants of human α-synuclein.

Recombinant wild-type (●), A53T (▪), A30P (*) and E64K (⋄) human α-synuclein were coated on ELISA plates (2 μg/ml) and probed with various concentrations of NI202.12F4.

Fig.5 Chronic treatment with NI-202.12F4 improves motor performance in α-synuclein A53T transgenic mice.

NI-202.12F4 treated animals required significantly less time to turn downwards (t-turn; 1.7±0.3 vs. 4.6±0.6 sec, p=0.0002, two-tailed Student's t-test).

Fig.6 Chronic treatment of α-synuclein A53T transgenic mice with NI-202.12F4 results in elevated plasma levels of human A53T α-synuclein.

Plasma samples were prepared from 12.5 month old α-synuclein A53T transgenic mice that had been treated weekly i.p. for 2 months with 5 mg/kg NI-202.12F4 or PBS. Blood was taken 24 hrs after last application.